CREDIT AGREEMENT Dated as of July 3, 2018 between SPARK THERAPEUTICS, INC., as the Borrower, and WELLS FARGO BANK, NATIONAL ASSOCIATION, as the LenderCredit Agreement • November 6th, 2018 • Spark Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
This CREDIT AGREEMENT is entered into as of July 3, 2018, between SPARK THERAPEUTICS, INC., a Delaware corporation (the “Borrower”), and WELLS FARGO BANK, NATIONAL ASSOCIATION, (the “Lender”).
CASH COLLATERAL AGREEMENTCash Collateral Agreement • November 6th, 2018 • Spark Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
This CASH COLLATERAL AGREEMENT (this “Agreement”), dated as of July 3, 2018, is entered into by and between SPARK THERAPEUTICS, INC., a Delaware corporation (the “Company”) and WELLS FARGO BANK, NATIONAL ASSOCIATION (the “Lender”) in favor of the Lender and the other Secured Parties under (and as such term is defined in) that certain Credit Agreement, dated as of July 3, 2018 (as amended, amended and restated, supplemented, replaced or otherwise modified from time to time, the “Credit Agreement”), between the Company and the Lender.
DEDICATED MANUFACTURING AND COMMERCIAL SUPPLY AGREEMENTDedicated Manufacturing and Commercial Supply Agreement • November 6th, 2018 • Spark Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
This DEDICATED MANUFACTURING AND COMMERCIAL SUPPLY AGREEMENT (this “Agreement”), effective as of this 3rd day of August, 2018 (the “Effective Date”), between, Spark Therapeutics, Inc., a Delaware corporation with an office at 3737 Market Street, Suite 1300, Philadelphia, PA 19104 (“Customer”), and Brammer Bio MA, LLC, a Delaware limited liability company with offices at 250 Binney Street, Cambridge, MA 02142 (“Brammer”). Customer and Brammer are referred to herein each as a “Party” and collectively as the “Parties.”
